CG Pharmaceuticals to Present at 2024 ASCO Annual Meeting on June 1

ORINDA, Calif. – CG Pharmaceuticals, a biopharmaceutical company focused on metastatic pancreatic ductal adenocarcinoma (PDAC) maintenance therapy, is set to feature Dr. Christos Fountzilas from Roswell Park Comprehensive Cancer Center at the ASCO Annual Meeting in Chicago on June 1st. The presentation, scheduled between 1:30 – 4:30 PM CDT during the Gastrointestinal Cancer session, will highlight findings from their completed Phase 1b trial and the ongoing Phase 2 clinical trial.

The Phase 2 study began treating its first patient on January 9th, 2024, and continues to recruit patients across roughly 25 institutions in the United States. This trial focuses on metastatic PDAC patients who have not shown disease progression post-treatment with FOLFIRINOX, mFOLFIRINOX, or NALIRIFOX. In this phase, patients are randomized to receive either a combination of ivaltinostat and capecitabine or capecitabine alone. The primary goal is to assess ivaltinostat's effect on progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), and overall survival (OS).

Ivaltinostat is a promising therapeutic candidate targeting pancreatic ductal adenocarcinoma by inhibiting histone deacetylase enzymatic activity. It has been evaluated for both solid tumors and hematologic malignancies, positioning it as a potential first-in-class treatment option.

CG Pharmaceuticals operates out of the San Francisco Bay Area and is dedicated to developing innovative cancer therapies that enhance patient outcomes. The company's strategic focus, financial positioning, and product development plans are subject to inherent risks and uncertainties, which could significantly impact actual results.